Atossa Genetics prices IPO at $5, the midpoint of the range

By Renaissance Capital,

Shutterstock photo

Atossa Genetics, which develops diagnostic tests and treatments for breast cancer, raised $4 million by offering 800,000 shares at $5, the midpoint of the range of $4 to $6. Atossa Genetics plans to list on the NASDAQ under the symbol ATOS. Dawson James acted as the sole bookrunner on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: ATOS

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by